GENETHERA, INC. (OTCMKTS:GTHR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGMENTS OF CERTAIN OFFICERS

On April 2, 2018 GeneThera’s Board of Directors terminated Bruce Winslett and Jorgen Frandsen appointment as Members of the On the same day GeneThera BOD appointed Fred Oeschger and Jeremiah Bartley MD. to the Company’s Board of Directors. Mr. Oeschger is the President of a plumbing and heating oil company located in Vermont. He is also the Owner of a truck company delivering hating oil and diesel fuel in the Northeast United States. Mr. Oeshhger is a very successful commercial real estate investor. He owns multiple commercial properties throughout the United States. Fred Oscheger has been a Member of the Board of a Financial Institution for the past twelve years.

Dr. Jeremiah Bartley is the Director of Women’s Health Care at Rocky Mountain Internal Medicine in Denver, Colorado. He is a past President of the Colorado Section of the American College of Obstetrics and Gynecology. Dr. Bartley was a Member of the Hospital Provider Fee Oversight and Advisory Board from 2009 to 2016. Dr. Bartley receive a BA from Yale University and MD degree from University of Miami. He completed his residency in Obstetrics and Gynecology at Case Western University.

About GENETHERA, INC. (OTCMKTS:GTHR)

GeneThera, Inc. (GeneThera) is a biotechnology company. The Company focuses on improving food safety by applying the molecular technologies to eradicate cross-over (zoonotic) diseases, such as Johne’s Disease, Mad Cow Disease, Chronic Wasting Disease and E.coli. The Company focuses on developing molecular diagnostic tests, therapeutics and vaccines to help control diseases in animals and humans. GeneThera has developed diagnostic assays for use in the agricultural and veterinary markets. The Company offers specific assays for Chronic Wasting Disease among elk and deer, and Mad Cow Disease among cattle. The Company is engaged in the development of E. coli (predominantly cattle) and Johne’s disease (predominantly dairy cattle and bison) diagnostics. GeneThera’s Integrated Technology Platform (ITP) is the foundation for fast-track ribosomal DNA (rDNA) vaccine development. The Company is working on the development of a recombinant DNA vaccine for Johne’s disease.